ArticleFrontiers in surgery2026
Gastric histiocytic sarcoma: a case report and literature review.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histiocytic sarcoma is an exceptionally rare and highly aggressive neoplasm that exhibits the morphological and immunophenotypic hallmarks of mature histiocytes. It is characterized typically by extranodal presentation and a dismal clinical course, particularly in patients with disseminated disease. A history of hematolymphoid disorder can be identified in a subset of patients, suggesting transdifferentiation of a preexisting hematolymphoid neoplasm in its pathogenesis. A 38-year-old male patient presented for consultation following the detection of a gastric mass during a routine health examination. Subsequent multimodal evaluation, comprising abdominal computed tomography (CT), positron emission tomography-CT, and gastroscopy, indicated a high probability of malignancy, necessitating surgical resection. Comprehensive histopathological and immunohistochemical analyses confirmed the diagnosis of HS, and next-generation sequencing further corroborated this diagnosis. Despite surgical intervention, the patient succumbed to rapid disease progression within six months, further highlighting the intractable nature of this rare malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.